Lung Cancer News

Religiously tailored text messages intended to decrease smoking during Ramadan were “feasible and acceptable” among Muslim men in Minnesota, results of a single-arm observational study showed.

The FDA granted priority review to lorlatinib for first-line treatment of anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, according to the agent’s manufacturer.

Bristol Myers Squibb withdrew nivolumab from the U.S. market for the treatment of patients with small cell lung cancer that progressed after platinum-based chemotherapy and at least one other therapy, according to a press release.

Lower oral microbiome diversity and an abundance of specific taxa in the respiratory tract may be associated with greater risk for lung cancer in never smokers, researchers reported in Thorax.

Melissa Johnson, MD, has been appointed program director of lung cancer research for Sarah Cannon.

Women who underwent pulmonary resections for lung cancer had a significantly better prognosis compared with men, researchers reported in Chest.

The FDA approved osimertinib as adjuvant therapy for patients with non-small cell lung cancer with EGFR mutations.

The FDA granted breakthrough therapy designation to sotorasib for the treatment of certain patients with non-small cell lung cancer, according to the agent’s manufacturer.

A randomized phase 3 trial that evaluated lurbinectedin plus doxorubicin vs. physician’s choice of therapy for adults with pretreated small cell lung cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer.

Patients who underwent lung cancer screening had a significant reduction in mortality associated with the disease, although it came with a “tradeoff” of likely overdiagnosis, according to a recent meta-analysis.